Open AccessAnti-PD-1 treatment-induced immediate central diabetes insipidus: a case report
Author(s) -
Mengxia Yu,
Lirong Liu,
Pengfei Shi,
Hong Zhou,
Shenxian Qian,
Kuang Chen
Publication year - 2021
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2020-0334
Subject(s) - diabetes insipidus , medicine , polyuria , rituximab , lymphoma , complication , pediatrics , salvage therapy , diabetes mellitus , surgery , chemotherapy , oncology , endocrinology
Modulating PD-1 expression can constrain tumor growth. Hodgkin's lymphoma patients commonly express PD-L1 on tumor cells. We report the case of a 60-year-old male patient with relapsed classical Hodgkin's lymphoma who suffered from immediate-onset chill, hyperthermia and polyuria following initial treatment with sintilimab, an anti-PD-1 monoclonal antibody. The results revealed central diabetes insipidus (cDI). After 3 months of treatment with glucocorticoids and desmopressin acetate, his symptoms and the results were consistent with the resolution of cDI and the treatment course was discontinued. Diabetes insipidus is a rare complication of immunotherapeutic treatment, and this is the first case report to our knowledge to have described immediate-onset cDI caused by anti-PD-1 treatment.